Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial

Blood Cells, Molecules, and Diseases

Volumn 28, Issue 2, 2002, Pages 196-208

  Maggio, Aurelio ^a   D'Amico, Gennaro ^a   Morabito, Alberto ^b   Capra, Marcello ^c   Ciaccio, Calogero ^d   Cianciulli, Paolo ^e   Di Gregorio, Felicia ^f   Garozzo, Giovanni ^g   Malizia, Roberto ^h   Magnano, Carmelo ⁱ   Mangiagli, Antonino ^j   Quarta, Giovanni ^k   Rizzo, Michele ^l   D'Ascola, Domenico Giuseppe ^m   Rizzo, Aroldo ^a   Midiri, Massimo ⁿ  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Ospedale dei Bambini   (Italy)

^d Centro Trasfusionale   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

^f Centro di Microcitemia   (Italy)

^g Ospedale di Ragusa   (Italy)

^h Ospedale Villa Sofia   (Italy)

ⁱ GARIBALDI HOSPITAL   (Italy)

^j Centro Microcitemia   (Italy)

^k Divisione di Cardiologia   (Italy)

^l Centro Microcitemia   (Italy)

^m Ospedale di Reggio Calabria   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

Chelation therapy; L1 efficacy; L1 therapy; Oral chelation; Randomized clinical trial; Thalassemia major management

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THALASSEMIA MAJOR; TISSUE LEVEL; BETA THALASSEMIA; BLOOD; COMPARATIVE STUDY; IRON OVERLOAD; LIVER CIRRHOSIS; PATHOLOGY; PHARMACOKINETICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; DEFEROXAMINE; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER CIRRHOSIS; MALE; PYRIDONES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 18444390877     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2002.0510     Document Type: Article

References (43)

1. Survival in medically treated patients with homozygous β-thalassemia
2. Treatment of Cooley's anemia
3. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
4. Ocular and auditory toxicity of high dose subcutaneous deferoxamine therapy
5. Acute aphasia and loss of vision with desferrioxamine overdose
6. Sensorimotor neurophaty associated with high dose desferrioxamine
7. Short stature in homozygous β-thalassaemia is due to disproportionate truncal shortening
8. High-dose desferrioxamine as a cause of growth failure in thalassaemic patients
9. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine
10. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major
11. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning
12. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients
13. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
14. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major
15. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
16. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
17. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
18. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
19. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemeia: Indian trial
20. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies
21. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). H. Clinical observations
22. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
23. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
24. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
25. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey
26. Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting
27. Rapid and simultaneous typing of hemoglobin S, hemoglobin C and seven Mediterranean β-thalassemia mutations by covalent reverse dot-blot analysis: Application to prenatal diagnosis in Sicily
28. Deferiprone: A review of its clinical potential in iron overload in β-thalassemia major and other transfusion-dependent diseases
29. Il fegato nei pazienti affetti da β-thalassemia major: Determinazione della concentrazione di ferro con risonanza magnetica
30. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver
31. Hepatic iron overload in thalas-semic patients: Proposal and validation of an MRI method of assessment
32. Hepatic iron concentration: Noninvasive estimation by means of MR imaging techniques
33. Histological grading and staging of chronic hepatitis
34. Recommendations guiding physicians in biomedical research involving human subjects
35. Depletion of excessive liver iron stores with desferrioxamine
36. Iron state and hepatic disease in patients with thalassemia major treated with long-term subcutaneous desferrioxamine
37. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassemic patients
38. Iron chelation with oral deferiprone in patients with thalassemia
39. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation
40. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major
41. Safety profile of the oral iron chelator deferiprone: A multicentre study